



# MMV's Drug Discovery Portfolio



Curing Malaria Together [www.mmv.org](http://www.mmv.org)

Medicines for Malaria Venture



# Introduction

Win Gutteridge  
Chair, MMV's Expert **Scientific** Advisory Committee (ESAC)

Curing Malaria Together [www.mmv.org](http://www.mmv.org)



**Medicines for Malaria Venture**

# MMV's Driver

- Declaration in Seattle on 17 October 2007 by Bill and Melinda Gates (BMGF) and endorsed by Margaret Chan (DG WHO) that it was time to have another go at malaria:

# ERADICATION




# MMV's Product R&D Goals


- Short term:
  - Complete the development of its 4 ACTs for the treatment of *falciparum* malaria and extend their use to *vivax* malaria
- Medium term:
  - Develop treatments non-po patients with severe *falciparum* malaria, for the radical cure of *vivax* malaria and for the intermittent treatment of pregnant women and infants
- Long term:
  - Discover and develop non-artemisinin-based combination therapies (NACTs) to replace the ACTs



# MMV Portfolio 2007



# MMV Portfolio 2007




# Programme

- PSAC antagonists as lead compounds for antimalarial drug development: **Sanjay Desai**
- Novel inhibitors of DHFR: **Yongyuth Yuthavong**
- Next generation synthetic peroxide antimalarials: **Sue Charman**
- 4-Pyridones as putative antimalarials: **Domingo Gargallo**
- Concluding remarks: **Win Gutteridge**



# Programme

- PSAC antagonists as lead compounds for antimalarial drug development: Sanjay
- Novel inhibitors of P... with Yuthavong
- Second generation antimalarials: Sue Charman
- 4-Pyridones as ... ningo Gargallo
- Concluding remarks







# MMV's Drug Discovery Portfolio



Curing Malaria Together [www.mmv.org](http://www.mmv.org)

Medicines for Malaria Venture